title: Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
abstract: We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire-Female (SQOL-F), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were completed at baseline and week 12. Tolterodine ER (n = 201; mean +/- SD age, 49 +/- 12 years) reduced UUI episodes (P = 0.0029), total (P = 0.0006) and OAB (P < 0.0001) micturitions, and pad use per 24 h (P = 0.0024), and was associated with improvements in SQOL-F (P = 0.004), PISQ total (P = 0.009), and HAD Anxiety (P = 0.03) scores versus placebo (n = 210; mean +/- SD age, 47 +/- 12 years). OAB symptoms improved with tolterodine ER as did the scores of sexual health and anxiety measures in sexually active women with OAB.
authors.affiliation: Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, MSC10-5580 Albuquerque, NM, 87131, USA. RRogers@salud.unm.edu
authors.forename: Rebecca
authors.initials: R
authors.lastname: Rogers
authors.forename: Gloria
authors.initials: G
authors.lastname: Bachmann
authors.forename: Zhanna
authors.initials: Z
authors.lastname: Jumadilova
authors.forename: Franklin
authors.initials: F
authors.lastname: Sun
authors.forename: Jon D
authors.initials: JD
authors.lastname: Morrow
authors.forename: Zhonghong
authors.initials: Z
authors.lastname: Guan
authors.forename: Tamara
authors.initials: T
authors.lastname: Bavendam
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D004311:Double-Blind Method; D004644:Emotions / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology*; D019529:Sexuality / Q000502:physiology*; D011795:Surveys and Questionnaires; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate